The story will be updated after the study's presentation Friday afternoon. Please check back later. | About three years after a phase 3 flop led Takeda to withdraw its Exkivity from the EGFR exon 20 ...

AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...

With China's growing dominance in the biopharma sector as a hotspot for drug asse | A group of over 20 global pharma leaders ...

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

As AbbVie continues to capitalize on its ImmunoGen deal, the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FDA finish ...

Kaléo has launched the “AUVI-Q Speaks Up” campaign to share patients’, caregivers’ and healthcare providers’ stories about life with severe allergies. The company sells AUVI-Q, an epinephrine ...

Outlook Therapeutics has notched a win in its uphill battle to commercialize an ophthalmic version of Roche’s Avastin ...

In yet another round of Big Pharma layoffs in New Jersey, Johnson & Johnson is dismissing 56 employees at its corporate headquarters in New Brunswick, according (PDF) to a state Worker Adjustment and ...

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over ...

Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials and is now at the FDA’s doorstep, with an approval decision expected next month.

Placement on the plenary session of the upcoming ASCO 2026 annual meeting has significantly elevated enthusiasm around Akeso’s first-line non-small cell lung cancer data for its Summit ...

Amid a nearly $1 billion GLP-1 manufacturing expansion that began in 2024, CMDO CordenPharma is doubling down on its peptide capacity ambitions. The company—which already boasts production operations ...